How should I manage euglycemic diabetic ketoacidosis caused by empagliflozin—should I use an intravenous insulin infusion instead of a subcutaneous sliding‑scale regimen, and what fluid and electrolyte protocol is recommended?

Management of Euglycemic Diabetic Ketoacidosis from Empagliflozin

For empagliflozin-induced euglycemic DKA, you must use a continuous intravenous insulin infusion (NOT subcutaneous sliding scale) combined with high-calorie dextrose-containing fluids to maintain glucose between 150-250 mg/dL while correcting the acidosis. 1, 2, 3

Why IV Insulin is Mandatory

Subcutaneous sliding-scale insulin is completely inappropriate for any form of DKA, including euglycemic DKA. The FDA label explicitly warns that ketoacidosis from empagliflozin is a serious, life-threatening condition requiring urgent hospitalization, and treatment requires insulin infusion with fluid and carbohydrate replacement 3. Current guidelines uniformly recommend continuous IV insulin infusion for all moderate-to-severe DKA 1, 2.

The critical difference in euglycemic DKA: Traditional DKA protocols that titrate insulin based on glucose levels fail here because glucose is already normal or near-normal (often <250 mg/dL) 3, 4. This leads to inadequate insulin delivery and prolonged acidosis.

The Specific Protocol

Insulin Management

• Start fixed-rate IV insulin infusion at 0.05-0.1 units/kg/hour 1, 4
• Do NOT reduce or stop insulin based on glucose levels
• The insulin is needed to suppress ketogenesis, not just lower glucose
• Continue until anion gap normalizes and ketones clear (β-hydroxybutyrate <1.0 mmol/L)

Fluid and Dextrose Protocol

• Begin with 0.9% normal saline for initial volume resuscitation 1, 2
• Once glucose approaches 150-200 mg/dL, switch to dextrose-containing fluids (D5 or D10 in 0.45% saline) 4, 5
• Target glucose range: 150-250 mg/dL during treatment 2, 5
• High-calorie glucose infusion (up to 200-300g/day) may be needed to suppress ketogenesis while maintaining adequate insulin delivery 5
• Titrate dextrose concentration UP (not insulin down) if glucose drops below 150 mg/dL

Electrolyte Management

Potassium is critical: Hypokalaemia occurs in ~50% of DKA cases and severe hypokalaemia (<2.5 mEq/L) increases mortality 1

• If K+ <3.5 mEq/L: Hold insulin, give potassium replacement, recheck every 2 hours 2
• If K+ 3.5-5.0 mEq/L: Add 20-40 mEq potassium to each liter of IV fluid to maintain K+ 4-5 mEq/L 2
• If K+ >5.0 mEq/L: No supplementation needed initially, but monitor closely 2

Key Pitfalls to Avoid

1. Stopping insulin too early because glucose is normal - This is the most common error. The acidosis will persist or worsen 4, 5, 6.

2. Failing to recognize euglycemic DKA - The FDA warns that ketoacidosis may be present even with glucose <250 mg/dL 3. Check β-hydroxybutyrate in any patient on empagliflozin presenting with metabolic acidosis, regardless of glucose level 7, 8.

3. Inadequate dextrose supplementation - If you don't give enough glucose, ketogenesis continues despite insulin 5, 6. Recent evidence shows high-calorie glucose infusion (with tight glycemic control via insulin) is essential for refractory cases 5.

4. Attributing acidosis to other causes - Concurrent surgical complications or sepsis can mask euglycemic DKA, leading to delayed diagnosis 7. If acidosis persists after addressing the apparent surgical cause, measure ketones.

Monitoring Requirements

• Blood glucose: Every 1-2 hours initially
• Electrolytes, renal function, venous pH: Every 2-4 hours until stable 2
• β-hydroxybutyrate: At presentation and periodically to confirm resolution
• Anion gap: Calculate with each chemistry panel

Resolution Criteria

Continue IV insulin and dextrose until ALL of the following are met:

• Anion gap <12 mEq/L
• Venous pH >7.30
• Bicarbonate >18 mEq/L
• β-hydroxybutyrate <1.0 mmol/L
• Patient able to eat and drink 2

Transition to Subcutaneous Insulin

Once resolved, give subcutaneous basal insulin 2-4 hours BEFORE stopping the IV infusion to prevent rebound ketoacidosis 2. The total daily subcutaneous dose can be estimated from the average hourly IV insulin rate over the preceding 12 hours (e.g., 1.5 units/hour × 24 = 36 units/day total) 1.

Prevention

Empagliflozin must be discontinued 3-4 days before any elective surgery 2. The FDA label recommends temporarily discontinuing in situations predisposing to ketoacidosis: prolonged fasting, acute illness, surgery, reduced caloric intake, or alcohol use 3.